Wve-006
Alpha-1 Antitrypsin Deficiency
Wave Life Sciences USA, Inc.Phase 1/2Active
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 44/ 100
- Competitive Position
- 95/ 100
Competitive context
24 Active assets in the Alpha-1 Antitrypsin Deficiency cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Alpha-1-Proteinase Inhibitor Grifols Therapeutics LLC | Phase 4 | A |
.ALPHA.-1 PROTEASE INHIBITOR Grifols Therapeutics LLC | Phase 4 | A |
NORMAL HUMAN SERUM ALBUMIN Baxalta now part of Shire | Phase 4 | BBB |
.ALPHA.-1 PROTEASE INHIBITOR Grifols Therapeutics LLC | Phase 3 | BB |
Fazirsiran Takeda | Phase 3 | BB |
View all 50 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →